Innovation Pharmaceuticals Inc (IPIX)

[BooDog]

Enrollment has been completed in the second cohort of the Phase 2 open label Proof-of-Concept trial evaluating Brilacidin as a new treatment for mild-to-moderate ulcerative proctitis/ulcerative proctosigmoiditis, two types of inflammatory bowel disease.

http://www.cellceutix.com/press-release/2017/1/17/cellceutix-completes-enrollment-in-second-of-three-planned-cohorts-in-phase-2-clinical-trial-of-brilacidin-for-inflammatory-bowel-disease

There are big eyes on Cellceutix for very good reasons. The pipeline continues to impress and move forward. It wouldn't surprise me one bit if an institutional picks up a very large chunk just to squelch the shorts.

Message in reply to:

The absurdity of the panic is beyond crazy. Lost in the chaos is what appears to be a very fine ongoing study again IBD, one of the hottest and most lucrative dealmaking indications. The company will apparently soon have four Phase 2 trials ongoing. Weak minds and suckers for lies will be the end losers. Shorts like Mako will burn in the end with epic proportions if either Prurisol, Or the two Brilacidin trials deliver in a few months. It will be a life changing event for those invested and certainly a life changing event for the shorts. Believe in the science not the lies. We lost a dime today, but in no sense has it changed the science. Big Pharma is zeroed in not on dime price swings but on trial results, of which CTIX will release four in 2017, so it's without surprise that short activity is increasing and only will continue to as trial readouts near...